1.. Introduction
================

Antiarrhythmic drugs we can use for refractory arrhythmias in emergent care settings are confined to a few types. Intravenous amiodarone hydrochloride (AMD) is a class III antiarrhythmic drug that has diverse electrophysiological actions and can block multiple channels, including the rapid component of the delayed rectifier potassium current (I~Kr~), the slowly activating delayed rectifier K^+^ currents (I~Ks~), I~Ca-L~ and I~Na~ channel and beta receptor, and has been widely used for the management of emergent patients \[[@b1-pharmaceuticals-04-00794]-[@b3-pharmaceuticals-04-00794]\] and is recommended in the 2005 AHA guidelines for antiarrhythmic therapy in patients with shock-refractory ventricular fibrillation (VF) \[[@b4-pharmaceuticals-04-00794]\].

Nifekalant hydrochloride (NIF) is also an intravenously administered class III antiarrythmic drug used mainly in Japan \[[@b5-pharmaceuticals-04-00794]\]. NIF selectively blocks I~Kr~ and prolongs the refractory period. NIF has been found to have a significant antiarrhythmic effect to terminate shock-refractory lethal ventricular arrhythmias \[[@b6-pharmaceuticals-04-00794]-[@b11-pharmaceuticals-04-00794]\]. NIF has also been reported to suppress the induction of VT and VF induced by programmed electrical stimulation \[[@b11-pharmaceuticals-04-00794]\]. NIF have several advantageous effects as a pure I~Kr~ blocker when used particularly in emergent care settings. First, NIF has no negative inotropic effect and therefore has least impact on hemodynamics. Second, NIF has rapid onset of action and clearance. Third, as with other selective I~Kr~ blockers, NIF reduces the defibrillation threshold \[[@b12-pharmaceuticals-04-00794]\]. Considering the above, it may make sense clinically to use NIF as the initial drug of choice for emergent care of lethal arrhythmias in Japan. However, NIF cannot always achieve the desired effect and we occasionally experience cases of NIF-resistant arrhythmias. Here, we report 11 severe heart failure cases with NIF-resistant lethal arrhythmia, and we examined the effects of intravenous AMD in those patients.

2.. Materials and Methods
=========================

2.1.. Patients
--------------

Eleven consecutive severe heart failure patients who had received intravenous AMD for treatment of NIF-resistant arrhythmias in four hospitals (Okayama University Hospital, National Hospital Organization Iwakuni Medical Center, Cardiovascular Center Sakakibara Hospital, and Okayama Redcross Hospital) between 2000 and 2008 were included in this study, and retrospective analysis was performed.

NIF was initially administered at the standard dose and the dose was increased as needed in 0.05-0.1 mg/hr increments with careful ECG monitoring so that the QTc interval would not exceed 0.55 sec^1/2^. AMD had been administered at the basis of the formally recommended dose in the US. Bolus infusion was avoided and maintenance dose was flexibly reduced depending on the patient\'s condition. To ensure objective assessment, physicians who were not directly involved in the treatment organized an efficacy evaluation committee and assessed each case report form.

Patients were considered to have "severe heart failure" if their condition before use of NIF or AMD was (i) New York Heart Association classification IV or (ii) left ventricular ejection fraction (LVEF)\< 40%, (iii) if they needed to be managed with a cardiac support device such as a percutaneous cardiopulmonary support system (PCPS), intra-aortic balloon pumping (IABP) or a left ventricular assist device (LVAD), (iv) if they needed to be managed with intubation, (v) if they were in cardiogenic shock or (vi) if they were in cardiopulmonary arrest. The investigation conformed to the principles outlined in the Declaration of Helsinki.

2.2.. Clinical Assessment
-------------------------

Twelve-lead ECG was repeatedly recorded, and heart rate, Bazzet-corrected QT interval (QTc) and blood pressure were checked at appropriate times. Patient outcome (alive or dead) was investigated 30 days after the start of drug administration.

2.3.. Efficacy Evaluation
-------------------------

### 2.3.1.. Termination of Arrhythmias

NIF or AMD was assessed in terminating VT/VF or AF by the following criteria described previously \[[@b7-pharmaceuticals-04-00794]\]: (i) VT/VF or AF successfully terminated by bolus or continuous administration of NIF or AMD and (ii) VT/VF or AF not terminated by DC shock before intravenous administration of NIF or AMD but successfully terminated by additional DC shock after use of NIF or AMD (regarded as "enhancement of defibrillating effect"). Cases were judged "not evaluable" when another antiarrhythmic drug was used at the same time (or immediately after) administration of NIF or AMD.

### 2.3.2.. Prevention of Recurrence of Arrhythmias

NIF or AMD was assessed as "effective" in preventing recurrence of VT/VF or AF on the basis of the following criteria described previously: (i) complete suppression of the recurrence of sustained VT/VF or AF during maintenance infusion of the drug, (ii) recurrence during maintenance infusion of the drug but not after increase in the dose of NIF or AMD, (iii) complete suppression, maintenance infusion of the drug, of the recurrence of sustained VT/VF, which had occurred at least twice before intravenous administration of NIF or AMD. The observation time for assessment of the efficacy was set to 24 hours.

2.4.. Safety Evaluation
-----------------------

We defined clinical signs and abnormal changes in laboratory test results which were thought to be related to the drugs as adverse reactions.

2.5.. Statistics
----------------

Data are expressed as mean values ± SD. Comparisons of heart rate and QTc interval at baseline and during administration of NIF and AMD were made using one-way repeated analysis of variance followed by Bonferroni correction, and categorical data and percentage frequencies were analyzed by the chi-square test (Dr SPSS II for windows). A value of p \< 0.05 was considered to be statistically significant.

3.. Results
===========

3.1.. Patients\' Characteristics
--------------------------------

The patients\' characteristics are summarized in [Table 1](#t1-pharmaceuticals-04-00794){ref-type="table"}. A total of 11 patients in whom arrhythmias could not be controlled by other antiarrhythmic drugs were examined. The patients included seven males and four females aged from 0.8 to 79 years (mean age: 53 ± 20 years).

Underlying heart diseases were myocarditis in two patients, acute myocardial infarction (AMI) in seven patients, dilated cardiomyopathy in one patient and non-obstructive hypertrophic cardiomyopathy in one patient. Clinical arrhythmias were VF alone in two patients, VT alone in three patients, VT/VF in one patient, VT/VF/AF in one patient, VT/AF in three patients and AF alone in one patient. Nine patients had LVEF≤ 30%, and mean LVEF was 30 ± 13%. There were nine patients who received concurrent treatment with catecholamine. Seven patients required the use of IABP and six patients required PCPS for uncontrolled VT or VF with hemodynamic collapse.

3.2.. Intravenous Administration of NIF and AMD
-----------------------------------------------

A single bolus administration of NIF (0.3-0.6 mg/kg) was followed by a maintenance dose of 0.15-0.50 mg/kg/h. AMD was administered at several doses ([Table 2](#t2-pharmaceuticals-04-00794){ref-type="table"} and [Table 3](#t3-pharmaceuticals-04-00794){ref-type="table"}). Bolus injection before continuous infusion was used in two patients and continuous infusion without bolus injection was used in nine patients. Mean maintenance doses of AMD were 484 ± 166 mg/day for VT/VF and 480 ± 110 mg/day for AF. In three patients (cases No. 5, No. 7 and No. 10), simultaneous infusion of NIF and AMD was used. In case No. 5, administration of NIF was stopped, but administration of AMD was continued, and we could therefore evaluate the efficacy of each drug independently. In the other two cases (case Nos. 7 and 10), we could not evaluate the effect of intravenous AMD independently.

3.3.. Antiarrhythmic Efficacy for Ventricular Arrhythmias
---------------------------------------------------------

[Table 2](#t2-pharmaceuticals-04-00794){ref-type="table"} shows the antiarrhythmic efficacy of NIF and AMD for ventricular arrhythmias. Ten patients who suffered from VT and/or VF were evaluated. NIF was administered to all patients at a mean dose of 0.39 ± 0.14 mg/kg as a bolus and at 0.34 ± 0.12 mg/kg/h as continuous infusion. After administration of NIF, VT/VF was terminated in seven of the 10 patients, but not preventive effect was obtained in any of the patients (NIF-resistance). During continuous NIF administration, TdP associated with excessive QT prolongation (0.670 sec^1/2^) was observed in one case (case No. 3). AMD alone terminated VT/VF in 8 (80%) of the 10 patients, and prevention of VT/VF was also achieved in eight (80%) of the 10 patients. In the other two patients (cases No. 7 and No. 10), both termination and prevention were achieved by simultaneous administration of NIF and AMD. Five of the 10 patients in our study died within one month, but there were no arrhythmic deaths ([Table 1](#t1-pharmaceuticals-04-00794){ref-type="table"}).

3.4.. Antiarrhythmic Efficacy for Atrial Arrhythmias
----------------------------------------------------

[Table 3](#t3-pharmaceuticals-04-00794){ref-type="table"} shows the antiarrhythmic efficacy of NIF and AMD for AF. AF was paroxysmal in all cases. Four patients who suffered from AF also had VT or VF, but none of the VT or VF episodes were promoted by AF. NIF was used in all patients at a mean dose of 0.36 ± 0.13 mg/kg as a bolus and at 0.34 ± 0.09 mg/kg/h as continuous infusion. Neither a terminative nor preventive effect was observed after administration of NIF in any of the patients (NIF-resistance). Intravenous AMD alone (continuous infusion at a mean dose of 480 ± 110 mg/day) resulted in termination of AF in four (80%) of the five patients and in prevention of AF in three (60%) of the five patients. In one patient (case No. 7), termination of AF was achieved by simultaneous administration of NIF and AMD.

3.5.. Effects on Heart Rate and ECG Parameters
----------------------------------------------

[Table 4](#t4-pharmaceuticals-04-00794){ref-type="table"} shows heart rate (HR) and QTc interval in all patients during administration of NIF and AMD. HR did not change during administration of NIF but significantly decreased after administration of AMD (NIF: 100 ± 35 *vs.* AMD: 69 ± 15/min, P \< 0.05). Significant QTc prolongation was observed during NIF administration (*vs.* baseline, p \< 0.01), but there was no difference in QTc interval during AMD administration (*vs.* baseline, p = NS) ([Table 4](#t4-pharmaceuticals-04-00794){ref-type="table"} and [Figure 1](#f1-pharmaceuticals-04-00794){ref-type="fig"}).

In three cases for which simultaneous administration of NIF and AMD was performed, AMD further prolonged the QTc interval that had already been prolonged by NIF (baseline: 0.466 ± 0.027, NIF: 0.554 ± 0.058, NIF + AMD: 0.577 ± 0.032 sec^1/2^).

3.6.. Adverse Effects
---------------------

During continuous NIF administration, TdP associated with excessive QT prolongation was observed in one case (case No. 3). During continuous AMD administration, significant adverse effects, including lung fibrosis and liver dysfunction, proarrhythmic effects and worsening of cardiac function were not observed in any of the patients in this study.

4.. Discussion
==============

The optimal use of antiarrhythmic drugs for refractory arrhythmia with severe heart failure has not been established. While both AMD and NIF have been reported to be efficacious for refractory arrhythmias, there has been no study on the effect of AMD on NIF-resistant arrhythmia in patients with severe heart failure. In this study, we found that intravenous AMD, a multi-channel (I~Kr~, I~Ks~, I~Na~ and I~Ca-L~) and beta receptor blocker \[[@b3-pharmaceuticals-04-00794]\], was effective for NIF (a selective I~Kr~ blocker)-resistant lethal arrhythmias in emergent cases with severe heart failure.

QTc interval was prolonged by NIF but not by AMD alone. Therefore, QT prolongation was not effective for inhibition of arrhythmias in these cases. Interestingly, we found that the QTc interval was prolonged by simultaneous use of NIF and AMD. This could be explained by the reverse use-dependent property of NIF, which means that the I~Kr~ blocking effect of NIF was augmented by decrement of HR caused by AMD. Thus, caution is needed in simultaneous use of NIF and AMD.

The present study showed high mortality, but during continuous AMD administration, significant adverse effects, including lung fibrosis and liver dysfunction, proarrhythmic effects and worsening of cardiac function were not observed in any of the patients in this study. However, long term treatment with amiodarone has no favorable effect on survival \[[@b13-pharmaceuticals-04-00794]\]. Careful use of amiodarone is needed in patients with severe heart failure.

AMD was administered when NIF was not effective for termination or prevention of VT/VF in this study. On the other hand, NIF might be effective in different cases that do not respond to intravenous AMD. Further studies are needed to clarify this point.

5.. Limitations
===============

Since the present study was a retrospective study, it has several limitations. First, it involves a small number of patients from four hospitals over eight years with substantial inhomogeneity in the patients\' background (ages from 1 year to 79 years), presenting arrhythmias (VT, VF or AF) and method of treatment (simultaneous or subsequent, with or without bolus infusion and) at varying doses of drugs in this study. This might have affected the efficacy of drugs. Second, since all of the 11 patients in this study were treated with other antiarrhythmic drugs before treatment with NIF and AMD, an additive effect cannot be ruled out. Therefore it is unclear whether the efficacy on arrhythmia and the change in ECG parameters in this study were due to either drug, combination of both drugs or other factors. To elucidate the interaction and joint effectiveness of a combination of these drugs, a prospective trial with treatment groups and well defined dosing regimens would be more suitable, albeit difficult to undertake under emergency conditions. Even for retrospective study, larger numbers and more stringent inclusion criteria would be required. Further studies are needed to clarify this point.

6.. Conclusions
===============

Intravenous AMD was effective in NIF-resistant lethal arrhythmias and was relatively safe in emergent cases with severe heart failure.

![Effects of administration of nifekalant hydrochloride (NIF) and intravenous amiodarone (AMD) on QTc interval.](pharmaceuticals-04-00794f1){#f1-pharmaceuticals-04-00794}

###### 

Patients\' characteristics.

  **Case No.**   **Age (y)**   **Gender**   **Heart disease**   **LVEF (%)**   **Arrhthymia**   **CA**   **IABP**   **PCPS**   **Outcome**
  -------------- ------------- ------------ ------------------- -------------- ---------------- -------- ---------- ---------- -------------------
  1              0.8           Female       myocarditis         25             VT               −        −          −          alive
  2              50            Female       myocarditis         27             VT               −        −          −          alive
  3              48            male         DCM                 25             VT/VF, AF        −        −          −          dead (thrombosis)
  4              63            male         HCM                 65             VF               −        −          −          alive
  5              65            male         AMI                 30             VF               −        −          −          alive
  6              62            male         AMI                 30             VT,AF            −        −          −          dead (infection)
  7              65            male         AMI                 25             VT, AF           −        −          −          dead (MOF)
  8              57            male         AMI                 20             VT               −        −          −          dead (MOF)
  9              45            male         AMI                 18             VT, AF           −        −          −          dead (MOF)
  10             50            Female       AMI                 30             VT/VF            −        −          −          alive
  11             79            Female       AMI                 37             AF               −        −          −          alive

LVEF, left ventricualr ejection fraction; CA, catecholamine; IABP, intraaortic baloon pumping; PCPS, percutaneous cardiopulmonary support; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; AMI, acute myocardial infarction; VT, ventricular tachycaridia; VF, ventricular fibrillation; AF, atrial fibrillation; MOF, multiple organ failure.

###### 

Effects of class-III drugs on ventricular arrhythmias.

  **Case No.**   **Dose of NIF**                                 **termination**   **prevention**     **Dose of AMD**                 **termination**                                               **prevention**
  -------------- ----------------------------------------------- ----------------- ------------------ ------------------------------- ------------------------------------------------------------- -------------------------------------------------------------
  1              0.3 mg/kg bolus + 0.5 mg/kg/h                   \+                −                  140 mg/day                      \+                                                            \+
  2              0.3 mg/kg bolus + 0.4 mg/kg/h                   −                 NE                 300 mg/day                      \+                                                            \+
  3              0.6 mg/kg bolus + 0.4 mg/kg/h                   \+                −                  600 mg/day                      \+                                                            \+
  4              0.3 mg/kg bolus + 0.4 mg/kg/h                   −                 NE                 125 mg bolus + 300-600 mg/day   \+                                                            \+
  5              0.3 mg/kg bolus + 0.4 mg/kg/h                   \+                −                  600 mg/day                      \+                                                            \+
  6              0.3 mg/kg bolus + 0.4 mg/kg/h                   \+                −                  600 mg/day                      \+                                                            \+
  7              0.3 mg/kg bolus + 0.3 mg/kg/h                   −                 NE                 400 mg/day                      NE[\*](#tfn3-pharmaceuticals-04-00794){ref-type="table-fn"}   NE[\*](#tfn3-pharmaceuticals-04-00794){ref-type="table-fn"}
  8              0.6 mg/kg bolus + 0.2 mg/kg/h                   \+                −                  150 mg bolus + 600 mg/day       \+                                                            \+
  9              0.3 mg/kg bolus + 0.2 mg/kg/h                   \+                −                  400 mg/day                      \+                                                            \+
  10             0.6 mg/kg bolus + 0.15 mg/kg/hr                 \+                −                  600 mg/day                      NE[\*](#tfn3-pharmaceuticals-04-00794){ref-type="table-fn"}   NE[\*](#tfn3-pharmaceuticals-04-00794){ref-type="table-fn"}
                                                                                                                                                                                                    
  mean           0.39 ± 0.14 mg/kg bolus + 0.34 ± 0.12 mg/kg/h                     484 ± 166 mg/day                                                                                                 

AMD, amiodarone; NIF, nifekalant hydrochloride; NE, not evaluated;

effective under the condition of simultaneous administration of AMD and NIF.

###### 

Effects of class III drugs on atrial arrhythmias.

  **Case No.**   **Dose of NIF**                                 **termination**   **prevention**     **Dose of AMD**   **termination**                                               **prevention**
  -------------- ----------------------------------------------- ----------------- ------------------ ----------------- ------------------------------------------------------------- ----------------
  3              0.6 mg/kg bolus + 0.4 mg/kg/h                   −                 −                  600 mg/day        \+                                                            \+
  6              0.3 mg/kg bolus + 0.4 mg/kg/h                   −                 −                  600 mg/day        \+                                                            −
  7              0.3 mg/kg bolus + 0.3 mg/kg/h                   −                 −                  400 mg/day        NE[\*](#tfn5-pharmaceuticals-04-00794){ref-type="table-fn"}   −
  9              0.3 mg/kg bolus + 0.2 mg/kg/h                   −                 −                  400 mg/day        \+                                                            \+
  11             0.3 mg/kg bolus + 0.4 mg/kg/h                   −                 −                  400 mg/day        \+                                                            \+
                                                                                                                                                                                      
  mean           0.36 ± 0.13 mg/kg bolus + 0.34 ± 0.09 mg/kg/h                     480 ± 110 mg/day                                                                                   

AF, atrial fibrillation; AMD, intravenous amiodarone; NIF, nifekalant hydrochloride; NE, not evaluated;

effective under the condition of simultaneous administration of NIF and AMD.

###### 

Electrocardiogaphical parameters.

  **Case No.**   **Baseline**                                                 **NIF**         **NIF+ AMD**[†](#tfn7-pharmaceuticals-04-00794){ref-type="table-fn"}   **AMD**                                                                                                      
  -------------- ------------------------------------------------------------ --------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------ --------- --------------- --------- ---------------------------------------------------------------------------
  1              181                                                          0.455           176                                                                    0.583                                                                                              75        0.515
  2              95                                                           0.479           NE                                                                     NE                                                                                                 100       0.438
  3              86[ˆ](#tfn8-pharmaceuticals-04-00794){ref-type="table-fn"}   0.490           86                                                                     0.670                                                                                              52        0.519
  4              VF                                                           VF              VF                                                                     VF                                                                                                 58        0.417
  5              102                                                          0.472           76                                                                     0.518                                                                    78        0.547           63        0.454
  6              50                                                           0.475           81                                                                     0.512                                                                                              80        0.471
  7              94                                                           0.466           NE                                                                     NE                                                                       90        0.574           NE        NE
  8              96                                                           0.504           81                                                                     0.562                                                                                              74        0.494
  9              84                                                           0.474           120[ˆ](#tfn8-pharmaceuticals-04-00794){ref-type="table-fn"}            0.573                                                                                              59        0.475
  10             97                                                           0.420           107                                                                    0.481                                                                    60        0.610           NE        NE
  11             62                                                           0.424           75                                                                     0.533                                                                                              60        0.460
  mean           95 ± 35                                                      0.466 ± 0.027   100 ± 35                                                               0.554 ± 0.058[\*](#tfn9-pharmaceuticals-04-00794){ref-type="table-fn"}   76 ± 15   0.577 ± 0.032   69 ± 15   0.471 ± 0.034[\*\*](#tfn10-pharmaceuticals-04-00794){ref-type="table-fn"}

HR, heart rate; QTc, corrected QT interval; AMD, amiodarone; NIF, nifekalant; NE, not evaluated; VF, ventricular fibrillation;

simultaneous administration of NIF and AMD;

status of AF;

P \< 0.01 *vs.* baseline,

P \< 0.05 *vs.* NIF.
